Author:
Scioli-Montoto Sebastian,Sbaraglini Maria Laura,Cisneros Jose Sebastian,Chain Cecilia Yamil,Ferretti Valeria,León Ignacio Esteban,Alvarez Vera Alejandra,Castro Guillermo Raul,Islan German Abel,Talevi Alan,Ruiz Maria Esperanza
Abstract
Pharmacological treatments of central nervous system diseases are always challenging due to the restrictions imposed by the blood–brain barrier: while some drugs can effectively cross it, many others, some antiepileptic drugs among them, display permeability issues to reach the site of action and exert their pharmacological effects. The development of last-generation therapeutic nanosystems capable of enhancing drug biodistribution has gained ground in the past few years. Lipid-based nanoparticles are promising systems aimed to improve or facilitate the passage of drugs through biological barriers, which have demonstrated their effectiveness in various therapeutic fields, without signs of associated toxicity. In the present work, nanostructured lipid carriers (NLCs) containing the antiepileptic drug phenobarbital were designed and optimized by a quality by design approach (QbD). The optimized formulation was characterized by its entrapment efficiency, particle size, polydispersity index, and Z potential. Thermal properties were analyzed by DSC and TGA, and morphology and crystal properties were analyzed by AFM, TEM, and XRD. Drug localization and possible interactions between the drug and the formulation components were evaluated using FTIR. In vitro release kinetic, cytotoxicity on non-tumoral mouse fibroblasts L929, and in vivo anticonvulsant activity in an animal model of acute seizures were studied as well. The optimized formulation resulted in spherical particles with a mean size of ca. 178 nm and 98.2% of entrapment efficiency, physically stable for more than a month. Results obtained from the physicochemical and in vitro release characterization suggested that the drug was incorporated into the lipid matrix losing its crystalline structure after the synthesis process and was then released following a slower kinetic in comparison with the conventional immediate-release formulation. The NLC was non-toxic against the selected cell line and capable of delivering the drug to the site of action in an adequate amount and time for therapeutic effects, with no appreciable neurotoxicity. Therefore, the developed system represents a promising alternative for the treatment of one of the most prevalent neurological diseases, epilepsy.
Reference70 articles.
1. Quantification and Evaluations of Catechin Hydrate Polymeric Nanoparticles Used in Brain Targeting for the Treatment of Epilepsy;Ahmad;Pharmaceutics,2020
2. Praziquantel-loaded Solid Lipid Nanoparticles: Production, Physicochemical Characterization, Release Profile, Cytotoxicity and In Vitro Activity against Schistosoma Mansoni;Andrade;J. Drug Deliv. Sci. Technol.,2020
3. Cerebral Expression of Drug Transporters in Epilepsy;Aronica;Adv. Drug Deliv. Rev.,2012
4. Controlled Release: Mechanisms and Rates;Baker,1975
5. Global, Regional, and National Burden of Epilepsy, 1990-2016: a Systematic Analysis for the Global Burden of Disease Study 2016;Beghi;Lancet Neurol.,2019
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献